Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)
…, JJ Callery, S Boyd, O Anunsittichai… - The Journal of …, 2023 - academic.oup.com
Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a …
…, M Abdad, S Keayarsa, O Anunsittichai… - The Lancet Infectious …, 2024 - thelancet.com
Background Effective antiviral drugs prevent hospitalisation and death from COVID-19.
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
…, C Cruz, JJ Callery, S Boyd, O Anunsittichai… - medRxiv, 2022 - medrxiv.org
Background Uncertainty over the therapeutic benefit provided by parenteral remdesivir in
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
[HTML][HTML] Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in …
…, P Maimongkol, O Anunsittichai… - International Journal of …, 2021 - Elsevier
Objectives To be effective, piperacillin/tazobactam (PTZ) unbound plasma levels need to be
above the minimum inhibitory concentration (MIC) at least 50% of the time between dosing …
above the minimum inhibitory concentration (MIC) at least 50% of the time between dosing …
[HTML][HTML] Intensification of antiretroviral treatment with raltegravir for pregnant women living with HIV at high risk of vertical transmission
…, S Anugulruengkitt, O Anunsittichai… - Journal of virus …, 2018 - Elsevier
Objectives: The rate of vertical HIV transmission for women at high risk of HIV transmission
stands at approximately 7.6%. In the present study we describe infant infection rates in …
stands at approximately 7.6%. In the present study we describe infant infection rates in …
[HTML][HTML] Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study
…, W Sukkummee, O Anunsittichai… - International Journal of …, 2021 - Elsevier
Objectives The aim of this study was to describe the population pharmacokinetics of intravenous
colistin use in children and to propose optimal dosage regimens. Methods A prospective…
colistin use in children and to propose optimal dosage regimens. Methods A prospective…
A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children
…, W Jantarabenjakul, S Anugulruengkitt, O Anunsittichai… - Vaccine, 2019 - Elsevier
Background World Health Organization changed the recommendation for pre-exposure
rabies prophylaxis from 3-dose to 2-dose regimen in 2018. Given limited data of 2-dose …
rabies prophylaxis from 3-dose to 2-dose regimen in 2018. Given limited data of 2-dose …
Husband's willingness-to-pay for HIV and syphilis screening at antenatal care clinic under the Thai universal coverage scheme
O Anunsittichai, K Pongpirul, T Puthanakit… - BMC Public Health, 2020 - Springer
Background Screening for sexually transmitted infection (STI) especially HIV as early detection
and treatment have been financially supported under the Thai Universal Coverage (UC) …
and treatment have been financially supported under the Thai Universal Coverage (UC) …
Nevirapine concentrations during the first month of life and maternal efavirenz washout in high-risk HIV-exposed infants receiving triple antiretroviral prophylaxis
S Anugulruengkitt, TR Cressey… - The Pediatric …, 2019 - journals.lww.com
Background: Triple-drug infant antiretroviral prophylaxis containing nevirapine (NVP) is
increasingly used to prevent HIV transmission among neonates at high risk of HIV infection. Our …
increasingly used to prevent HIV transmission among neonates at high risk of HIV infection. Our …
Safety of 6-week neonatal triple-combination antiretroviral postexposure prophylaxis in high-risk HIV-exposed infants
S Anugulruengkitt, P Suntarattiwong… - The Pediatric …, 2019 - journals.lww.com
Background: Combination antiretroviral drug regimens are increasingly preferred for neonatal
postexposure prophylaxis (PEP) among HIV-exposed infants with high-risk of transmission…
postexposure prophylaxis (PEP) among HIV-exposed infants with high-risk of transmission…
